<DOC>
	<DOCNO>NCT00824187</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety YAZ compare placebo treatment symptom relate Premenstrual Dysphoric Disorder ( PMDD ) .</brief_summary>
	<brief_title>YAZ Premenstrual Dysphoric Disorder ( PMDD ) China</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Chinese woman reproductive age 1845 year ( inclusive ) diagnosis Premenstrual Dysphoric Disorder ( PMDD ) Any formal psychotherapeutic counselling within 1 month screen visit ( Visit 1 ) use medication Premenstrual Syndrome ( PMS ) Premenstrual Dysphoric Disorder ( PMDD ) include , limited hormone , bromocriptine , GnRH agonists , vitamin B6 ( &gt; 100 mg ) , calcium supplement ( &gt; 1500 mg/day ) , anxiolytics antidepressant 3 month period prior Visit 1 Use sleep medication ( include melatonin ) 3 day per month . Pregnancy le 3 menstrual cycle since delivery , abortion lactation start treatment Obesity ( body mass index BMI &gt; 30 kg/m2 ) Hypersensitivity ingredient study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Premenstrual Dysphoric Disorder ( PMDD )</keyword>
	<keyword>Oral contraceptive</keyword>
</DOC>